Spinal Muscular Atrophy Market to grow at a CAGR of 14% - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Spinal Muscular Atrophy Market to grow at a CAGR of 14%

Description:

Spinal muscular atrophy (SMA) is one of the most common genomic disorders which are caused due to the loss of specialized nerve cells known as motor neurons in the brainstem and spinal cord. – PowerPoint PPT presentation

Number of Views:18
Slides: 13
Provided by: Renub-Research
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Spinal Muscular Atrophy Market to grow at a CAGR of 14%


1
Spinal Muscular Atrophy Market

2
Report Description and Highlights
Analyst View
Spinal muscular atrophy (SMA) is one of the most
common genomic disorders which are caused due to
the loss of specialized nerve cells known as
motor neurons in the brainstem and spinal cord.
The impairment of motor neurons leads to the
weakness and atrophy of muscles used for the
regular activities like crawling, sitting,
walking and the head movement. In worst cases,
the muscles used for breathing and swallowing
also get affected. On the basis of severity of
muscle weakness, the age of disease commencement,
there are four types of spinal muscular atrophy
namely type 1, type 2, type 3 and type 4. Type 1,
2 and 3 of spinal muscle atrophy appears in
childhood while type 4 appears in adulthood.
According to Renub Research forecast the global
Spinal Muscular Atrophy Market to grow at a CAGR
of 14 in the coming years. This high growth rate
is primarily due to good reimbursement options in
western countries, declining drug prices and
projected launch of new drugs.


3
Spinal Muscular Atrophy Market
One of the major growth drivers witnessing the
growth of spinal muscular atrophy market is
growing awareness of diagnosis and treatment of
spinal muscular atrophy during the forecast
period. The awareness about the spinal muscular
atrophy diagnosis and treatment is growing among
the patients. The recent outcome of spinal
muscular atrophy treatment further plays a
significant role in spreading awareness about the
disease.  Additionally, increasing government
and non-government support for the treatment and
diagnosis of spinal muscular atrophy further
boost the growth Global Spinal Muscular Atrophy
Market over the coming years. The government of
several countries across the world has developed
regulations to help medical professionals and
caregivers decide when to administer the cure
to the infants with spinal muscular atrophy. For
instance In 2018, the Canadian organization of
rare disorders signed a petition for funding
SPINRAZA for the treatment of Canadian patients
with spinal muscular atrophy. Furthermore, one of
the key factors attributing to the growth of the
spinal muscular atrophy market is the rising
investing by the key market players for the
research and development of new and effective
spinal muscular atrophy therapies. Spinal
muscular atrophy generally shows its symptoms in
early childhood and is a prime cause of mortality
in infants. According to Spinal Muscular Atrophy
(SMA) Foundation 2015 statistics, spinal muscular
atrophy has been affected nearly 10,000 to 25,000 
children and adults in the United States. The
rising incidence of damaged spinal muscular
atrophy gene amongthe infants around the world is
expected to boost the growth of spinal muscular
atrophy in the next couple of years. On the other
hand, the high cost of drugs and treatment is
likely to restrain the growth of spinal muscular
atrophy market over the forecast period. For
example, Biogens Spinraza (nusinersen) medicine
for spinal muscular atrophy (SMA) is estimated to
cost US 125,000 per injection, accounting huge
expense for the treatment.
4
Spinal Muscular Atrophy Market
Renub Research report titled Spinal Muscular
Atrophy Market Global Forecast by Countries
(United States, United Kingdom, France, Germany,
Spain, Italy Japan), Drugs (Spinraza, AVXS-101,
CK2127107, RG7916, Olesoxime LMI070), Companies
(Biogen Inc., Roche AG, Novartis AG, Cytokinetics
Inc) studies the global spinal muscular atrophy
market and provides an all-encompassing analysis
of the key growth drivers and challenges, market
trends, key players and their projections for the
future.

Read more here https//www.renub.com/global-spina
l-muscular-atrophy-market-nd.php
5
Spinal Muscular Atrophy Market Share Analysis
Global - Current Forecast for Spinal Muscular
Atrophy Patient Population Share (), 2017 - 2026
Source Renub Research Analysis
Note These are dummy figures
actual data given in the report
6
Spinal Muscular Atrophy Market
  • Market Summary
  • Country-wise, the report provides the Spinal
    muscular atrophy market and market

    share of United
    States, United Kingdom, France, Germany, Spain,
    Italy and Japan.
  • Number of Patients-wise the report provides the
    total treated patients population and
    population share of United States, United
    Kingdom, France, Germany, Spain, Italy and Japan.
  • Drug-wise, the report provides present and
    estimated global sales of Spinraza, AVXS-101,
    CK2127107, RG7916, Olesoxime LMI070.
  • Company-wise the report provides present and
    estimated global of Biogen Inc., Roche AG,
    Novartis AG and Cytokinetics Inc.
  • Drugs Clinical Phase Study, The report provides
    113 Drugs clinical study pipeline status Which is
    at present, globally in the various stage such as
    (Phase I, II and III) unknown status, recruiting,
    active, not recruiting, terminated or completed
    stage.


Request a free sample copy of the report
https//www.renub.com/request-sample-page.php?gtur
lspinal-muscular-atrophy-market-p.php
7
India Outbound Tourism MarketShare Analysis
Forecast for Spinal Muscular Atrophy Market by
Drugs Seles 2017 - 2026

Source Renub Research Analysis
Note These are dummy figures
actual data given in the report
8
Key Topics Covered in Spinal Muscular Atrophy
Market
1. Introduction 1.1 Market Definition
1.2
Currency Conversion 2. Research
Methodology 3. Executive Summary 4.
Global Spinal Muscular Atrophy Market and
Patients Analysis 4.1 Spinal Muscular Atrophy
Market 4.2 Spinal
Muscular Atrophy Patient Numbers 4.3 Spinal
Muscular Atrophy Treated Patient Number 5.
Share Analysis Global Spinal Muscular
Atrophy 5.1 Country Market Share
5.2 Patients Population Share
5.3 Treated Patients Share 6. United
States 6.1 Spinal Muscular Atrophy Market
6.2 Spinal Muscular
Atrophy Patient Numbers 6.3 Spinal Muscular
Atrophy Treated Patients
9
Key Topics Covered in Spinal Muscular Atrophy
Market
7. United Kingdom 7.1 Spinal Muscular
Atrophy Market
7.2 Spinal Muscular Atrophy Patient
Numbers 7.3 Spinal Muscular Atrophy Treated
Patient Numbers 8. Germany 8.1 Spinal
Muscular Atrophy Market
8.2 Spinal Muscular Atrophy
Patient Numbers 8.3 Spinal Muscular Atrophy
Treated Patients 9. Italy Spinal Muscular
Atrophy 9.1 Spinal Muscular Atrophy Market
9.2
Spinal Muscular Atrophy Patient Numbers 9.3
Spinal Muscular Atrophy Treated Patient
Numbers 10. France Spinal Muscular
Atrophy 10.1 Spinal Muscular Atrophy Market
10.2
Spinal Muscular Atrophy Patient Numbers 10.3
Spinal Muscular Atrophy Treated Patient
Numbers 11. Spain 11.1 Spinal Muscular
Atrophy Market
11.2 Spinal Muscular Atrophy Patient
Numbers 11.3 Spinal Muscular Atrophy Treated
Patient Numbers
10
Key Topics Covered in Spinal Muscular Atrophy
Market
12. Japan 12.1 Spinal Muscular Atrophy
Market
12.2 Spinal Muscular Atrophy
Patients 12.3 Spinal Muscular Atrophy Treated
Patient Numbers 13. Drugs Sales Spinal
Muscular Atrophy 13.1 Spinraza
13.2 AVXS-101
13.3
CK2127107 13.4 RG7916
13.5 Olesoxime
13.6 LMI070 14.
Spinal Muscular Atrophy Study Status
Analysis 14.1 Spinal Muscular Atrophy
Clinical Study
14.2 Spinal Muscular Atrophy Drugs
Development Pipeline 15. Growth Drivers 15.1
Increasing Funding for Research Development
15.2 Biogen Access
Programs 16. Challenges 16.1 High
Treatment Cost
16.2 Common
Side Effects
11
Key Topics Covered in Spinal Muscular Atrophy
Market
17. Biogen Inc. 17.1 Business
Overview 17.2 Initiatives/Strategies 17.3
Financial Insight 18. Novartis AG 18.1
Business Overview 18.2 Initiatives/Strategies 1
8.3 Financial Insight 19. Roche Holding
AG 19.1 Business Overview 19.2
Initiatives/Strategies 19.3 Financial
Insight 20. Cytokinetics, Inc. 20.1
Business Overview 20.2 Initiatives/Strategies 2
0.3 Financial Insight
12
Key Topics Covered in Drugs Pharmaceuticals
Market
Browse Related Report Epilepsy Drugs
Market Global Allergic Conjunctivitis
Market Contact Us Tel 1-678-302-0700 (US),
91-120-421-9822 (INDIA) Email info_at_renub.com
About PowerShow.com